Wyeth News

“Getting old sucks. No one wants to get old. But you know what's worse? The alternative. If you think about it, growing old is a heck of a lot better than not growing old.”

I have a friend who recently crossed the big 4-0. Forty years of age. He was more than a bit depressed about it. via Motley Fool

Comment?

For a long time, few drugs were developed for rheumatological diseases. It was considered unattractive from a commercial viewpoint since relatively few patients suffered from them. via The Biotech Stock Blog

Comment?

Merck announced that the FDA rejected its newest cholesterol-lowering drug , but reaffirmed guidance for the year. via Fool.com

Comment?

“Bob Ruffolo has been the driving force of our R&D progress, establishing Wyeth as one of the research leaders in the pharmaceutical industry”

Wyeth said Thursday that Robert Ruffolo will step down later this year as head of pharmaceutical research. via Philadelphia Business Journal

Comment?

“We look forward to Dr. Dohlsten's leadership as we work together to continue our success at Wyeth Research”

Robert R. Ruffolo, Jr., Ph.D. will retire as president, Wyeth Research and senior vice president, Wyeth , later this year. via Contract Pharma Breaking News

Comment?

Danish pharmaceutical group Lundbeck appointed on Tuesday Ulf Wiinberg as its new President and Chief Executive Officer. via PharmaGossip

Comment?

“Initiation of the SBI-087 Phase 1 clinical trial marks an important milestone in advancing our pipeline through our collaboration with Wyeth”

Main Category: Arthritis Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 22 Apr 2008 - 0:00 PDT rate article Trubion Pharmaceuticals Inc. via Medical News Today

Comment?

“Side effects associated with opioids, such as constipation, can be severe enough to limit pain management”

Federal regulators have approved the first drug meant to relieve constipation caused by narcotic painkillers, the drug's makers said Friday. via PhillyBurbs.com

3 comments

Progenics Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth , today announced that the U.S. Food and Drug Administration has approved RELISTOR subcutaneous injection for the treatment of ... via ClipSyndicate

Comment?

Drugmaker Wyeth said Thursday its Chairman Robert Essner will retire in late June to be replaced by Chief Executive Robert Poussot. via International Business Times

Comment?